Centessa Pharmaceuticals Plc Stock Working Capital
| CNTA Stock | USD 18.08 1.08 6.35% |
Centessa Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Centessa Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Centessa Stock. The fundamental analysis module provides a way to measure Centessa Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Centessa Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 275.7 M | 352.5 M | |
| Change In Working Capital | -18.9 M | -18 M |
Centessa | Working Capital |
Centessa Pharmaceuticals PLC Company Working Capital Analysis
Centessa Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Centessa Pharmaceuticals Working Capital | 275.71 M |
Most of Centessa Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Centessa Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Centessa Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Centessa Pharmaceuticals is extremely important. It helps to project a fair market value of Centessa Stock properly, considering its historical fundamentals such as Working Capital. Since Centessa Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Centessa Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Centessa Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Centessa Net Invested Capital
Net Invested Capital |
|
In accordance with the company's disclosures, Centessa Pharmaceuticals PLC has a Working Capital of 275.71 M. This is 35.23% lower than that of the Biotechnology sector and 48.81% lower than that of the Health Care industry. The working capital for all United States stocks is 81.35% higher than that of the company.
Centessa Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Centessa Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Centessa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Centessa Pharmaceuticals by comparing valuation metrics of similar companies.Centessa Pharmaceuticals is currently under evaluation in working capital category among its peers.
Centessa Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Centessa Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Centessa Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Centessa Fundamentals
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (22.68) % | ||||
| Current Valuation | 1.72 B | ||||
| Shares Outstanding | 128.57 M | ||||
| Shares Owned By Insiders | 1.39 % | ||||
| Shares Owned By Institutions | 78.00 % | ||||
| Number Of Shares Shorted | 2.15 M | ||||
| Price To Book | 7.49 X | ||||
| Price To Sales | 313.87 X | ||||
| Revenue | 6.88 M | ||||
| EBITDA | (171.13 M) | ||||
| Net Income | (151.67 M) | ||||
| Cash And Equivalents | 484.16 M | ||||
| Cash Per Share | 5.13 X | ||||
| Total Debt | 84.59 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 15.48 X | ||||
| Book Value Per Share | 2.54 X | ||||
| Cash Flow From Operations | (160.96 M) | ||||
| Short Ratio | 6.28 X | ||||
| Earnings Per Share | (1.55) X | ||||
| Target Price | 26.14 | ||||
| Number Of Employees | 72 | ||||
| Beta | 1.48 | ||||
| Market Capitalization | 2.24 B | ||||
| Total Asset | 362.97 M | ||||
| Retained Earnings | (752.95 M) | ||||
| Working Capital | 275.71 M | ||||
| Net Asset | 362.97 M |
About Centessa Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Centessa Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Centessa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Centessa Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Centessa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Centessa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Centessa Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Centessa Pharmaceuticals Plc Stock:Check out Centessa Pharmaceuticals Piotroski F Score and Centessa Pharmaceuticals Altman Z Score analysis. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. If investors know Centessa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centessa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 0.068 | Return On Assets (0.25) | Return On Equity (0.56) |
The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centessa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Centessa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centessa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.